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Summary The expression of the gp100 antigen is generally thought to be confined to cells of the melanocytic lineage, which makes the
protein a suitable melanoma-specific marker. Strikingly, after screening a panel of normal tissues, tumour samples and cell lines of non-
melanocytic origin, we found transcripts encoding gplOO in virtually every tissue and cell line tested. In contrast, tyrosinase and MART-
1/MelanA transcripts were detected only in cells of the melanocytic lineage. However, no gpl00 protein could be detected by either Western
blotting or cytotoxicity assays. Therefore, at the protein level, gp100 remains exclusive for cells of melanocytic origin despite its transcription
in many cell types. The major implication of this finding is that screening of patient material for gp100 expression should preferrably be
performed by antibody staining. Reverse transcriptase polymerase chain reaction (RT-PCR) can be employed, provided that it is performed in
a tightly controlled, semiquantitative setting.
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The molecular cloning oftumour-associated antigens has provided
new tools for the immunotherapy of cancer (reviewed in Van den
Eynde and Brichard, 1995). Now it has become feasible to immu-
nize cancer patients against these antigens to stimulate specifically
a cellular anti-tumour response (Marchand et al, 1995). To select
patients eligible for immunotherapeutic protocols, the antigenic
profiles of the patients' tumours must be characterized. This is
usually achieved by reverse transcriptase polymerase chain reac-
tion (RT-PCR) using RNA obtained from tumour samples when
available. An alternative source of tumour cells is whole blood,
which often contains numerous circulating residual tumour cells
(Brossart et al, 1995; Hoon et al, 1995). A suitable antigen to
target in melanoma is gplOO because itis thought to be specific for
cells of melanocytic lineage and it is adequately expressed in
melanoma cells. Expression in non-melanocytic cells, at least as
measured by antibody reactivity (Vennegoor et al, 1988) or
Northern analysis (Kawakami et al, 1994), is virtually absent. In a
routine RT-PCR screening of a number ofhuman tumour samples
and normal tissues, we noticed to our surprise that gplOO
transcripts were present in almost all materials tested, whereas
the protein was not detectable.
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MATERIALS AND METHODS
Tumour cell lines, samples and normal tissues
The renal cell carcinoma cell lines (RCC) LE-9104-RCC, LE-
921 l-RCC and LE-9415-RCC and the melanoma cell line Mel 603
were established in our laboratory. The RCC cell line SK-RC-7
was kindly provided by Dr E Oosterwijk (Department ofUrology,
Nijmegen University, The Netherlands). The RCC cell lines MZ-
1851-RCC and Camejo and melanoma cell lines MZ-2-mel and
MZ-7.4-mel were generously provided by Dr B Seliger (J
Gutenberg University, Mainz, Germany). The breast carcinoma
cell lines (BRCA) MCF-7 and SK-BR-3 were a gift from
Dr R Kuypers (Department of Pathology, Leiden University,
The Netherlands). The ovarian carcinoma cell lines (OVCA) COV
434 and COV 413A were established in our laboratory (Van den
Berg-Bakker et al, 1993). The melanoma cell line Mel 624 and
TIL 1200 lymphocytes were kindly provided by Dr Y Kawakami
(NCI, NIH, Bethesda, MD, USA). LE-8915-EBV and PS-EBV
are EBV-transformed B-cell lines established in our laboratory.
BLM is a melanoma cell line (Bakker et al, 1994). Normal tissues
were obtained after death from a woman without cancer. Fresh
retina was kindly provided by Dr M Jager (Department of
Ophthalmology, Leiden University, The Netherlands).
RNA isolation and cDNA synthesis
Total RNA was isolated by guanidine-thiocyanate (HSCN) extrac-
tion as described by Chomczynski and Sacchi (1987) or using
RNAzolB (Tel-Test, Friendswood, TX, USA). Before cDNA
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Table 1 Absence of cytotoxicity of TIL 1200 towards gplOO-positive RCC
cell lines
HLA-A*0201 gplOO % specific lysis (+ W6132)b
E:T ratio 30:1 10:1 3:1
Cell linea
BLM + - 2 2 0
(0) (-2) (-1)
Mel624 + + 58 37 17
(14) (7) (0)
LE-9104-RCC + + 2 0 0
(3) (1) (-1)
LE-9415-RCC + + - 2 - 2 -5
(5) (4) (3)
MZ-1851-RCC + + 3 4 2
(2) (-1) (1)
Camejo - + 0 0 0
(0) (1) (0)
aCell lines were tested in the presence of 10-fold excess cold K562. bThe
percentage of lysis after blocking with a 1:150 dilution of W6/32 is shown in
brackets.
synthesis, RNA from the cell lines was treated with DNAase I
(Gibco BRL, Breda, The Netherlands) for 30 min at 37°C followed
by phenol extraction and precipitation. RNA isolations from the
post-mortem tissues yielded such small amounts of RNA that we
did not perform DNAase treatment. For cDNA synthesis, 2 gg of
total RNA was reverse transcribed in first-strand buffer using 200
U ofM-MLV-RT (Gibco BRL) in the presence of40pmol ofoligo-
dT(18), 10 mm of each nucleotide, 200 nmol of DTT and 20 U of
RNasin (Gibco BRL) in a volume of 20 ,l. After 1 h at 42°C,
80g1 of sterile water was added (Van den Eynde et al, 1995).
The integrity ofthe cDNA was assessed by PCR for ,-actin.
Cell lines
PCR analysis
PCR was performed with 2.5 pl of the cDNA in 1 x PCR buffer,
2 mm magnesium chloride, dNTP (10 mm each), 10 pmol of
both primers, 0.05% WI, 0.5 U of Taq (Gibco BRL) in a volume
of 25 ,l. The PCR primers and programmes used were: 3-actin,
sense 5'-GGCATCGTGATGGACTCCG-3', antisense 5'-GCTG-
GAAGGTGGACAGCGA-3', 5 min at 94°C (1 min at 94°C,
2 min at 680C, 2 min at 72°C), 30x, 15 min at 72°C (Guilloux
et al, 1996). GplOO, sense 5'-TATFGAAAGTGCCGAGATCC-3',
antisense 5'-TGCAAGGACCACAGCCATC-3', 5 min at 940C
(1 min at 94°C, 1 min at 60°C, 1 min 72°C), 35x, 15 min at 72°C
(Adema et at, 1994). Tyrosinase, sense 5'-TTGGCAGATTGTCT-
GTAGCC-3', antisense 5'-AGGCATTGTGCATGCTGCTF-3',
5 min at 94°C (1 min at 94°C, 1 min at 60°C, 1 min at 72°C),
30 x, 15 min at 72°C (Smith et al, 1991). MART-l/MelanA, sense
5'-CTGACCCTACAAGATGCCAAGAG-3', antisense 5'-ATCA-
TGCATTGCAACATTTATTGATGGAG-3', 5 min at 94°C (1 min
at 940C, 2 min at 630C, 2 min at 720C) 35 x, 15 min at 72°C.
RAGE-1, sense 5'-GTGTCTCCTTCGTCTCTACTA-3', antisense
5'-GAGGTATTCCTGATCCTG-3', 5 min at 94°C (1 min at
94°C, 2 min at 560C, 3 min at 720C), 33 x, 15 min at 72°C
(Gaugler et al, 1996). The expected sizes of the PCR products
were: ,3-actin, 612 bp; gplOO, 360 bp; tyrosinase, 284 bp; MART-
l/MelanA, 603 bp; RAGE-1, 239 bp. A total of 15 g1 of the PCR
products was run on 2% agarose gels stained with ethidium
bromide. For semi-quantitative analysis 0.2 ,l of [32P]-dCTP was
added to the PCR mixture. For both gplOO and ,B-actin we
observed that amplification was linear at 25 and 21 cycles respec-
tively. After amplification, 10gl of the radioactive PCR products
was separated on 6% acrylamide gels and the intensities of the
PCR products were analysed using a Phosphor-Imager (Molecular
Dynamics, Sunnyvale, CA, USA).
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Figure 1 RT-PCR analysis of tumour-associated antigens. RT-PCR products of gp100, MART-1, RAGE-1, tyrosinase and f-actin transcripts in tumour cell lines
(left) and in normal tissues (right) were detected by ethidium bromide-stained 2% agarose gels. The samples were loaded as indicated on the top of the figure.
At the left, the positions of the kb marker are indicated. The upper band in the gpl 00 PCR indicated in the figure with an asterisk is the result of amplification of
genomic DNA
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Figure 2 Expression of gplOO protein in RCC cell lines as determined by
Western blotting. Lanes 1-4, RCC cell lines as indicated in the figure; lane 5,
COS-7 cells; lanes 6 and 7, melanoma cell lines as indicated. The numbers
on the left indicate the positions of the protein molecular weight marker
Western blotting
Cell lysates were prepared according to Vennegoor et al (1988).
An aliquot ofprotein was loaded (20gg per lane) on a 10% SDS-
PAGE. Human gplOO was detected by polyclonal rabbit antiserum
AZN-LAM, which was raised against the C-terminal 16-mer
peptide of human gplOO protein, and which was chemically
coupled to KLH (Pierce, Rockford, IL, USA). The serum was used
in a 1:3000 dilution for Western blotting. For immunodetection,
goat anti-rabbit-peroxidase (Zymed, SanFrancisco, CA, USA) and
ECL (Amersham, Buckinghamshire, UK) were used (MWJS
manuscript in preparation).
Cytotoxicity assay
Cytotoxicity towards the cell lines was performed as described
previously (Bakker et al, 1995). The target cells were pretreated
with 50 U ml-' y-IFN for48 h before testing. Antibody blocking of
cytotoxicity was performed by incubation of the chromium-
labelled target cells with W6/32 ascites in 1:100 dilution at 20°C
for 30 min. The final concentration ofW6/32 was 1:150.
RESULTS
gp100 but not MART-1/MelanA or tyrosinase transcripts
can be detected by RT-PCR in tumour cell lines and
normal tissues
To assess tumour antigen expression by a panel of tumour cell
lines including cell lines of non-melanocytic origin, we applied
RT-PCR for the currently known tumour-specific and melanocyte
lineage-specific antigens that may serve as targets for tumour-
specific cytotoxic T cells (CTL). Unexpectedly, we found gplOO
transcripts in cell lines ofnon-melanocytic origin, including 24/24
renal cell carcinoma cell lines, 8/8 ovarian carcinomacell lines and
6/6 breast carcinoma cell lines. In Figure 1, the gplOO-specific
PCR products of a representative selection of these different cell
lines are shown. In contrast, no tyrosinase or MART-l/MelanA
transcripts were detected, except in cells of melanocytic origin.
The RAGE-I cDNA, which was recently cloned from a renal cell
carcinoma cell line, was detected in RCC cell line MZ-1851-RCC
and in fresh retina (Figure 1) (Gaugler et al, 1996).
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Figure 3 Levels of gplOO expression in Mel 624, MCF-7 and JY cell lines.
cDNA as indicated in the figure was used in various dilutions in a radioactive
RT-PCR. The PCR products of ,B-actin (top) or gplOO (lower) were separated
on acrylamide gels and quantified by phosphor-imaging
gplOO has been reported to be specific for cells of the
melanocyte lineage. This was based on immunohistochemical
analysis and Northern analysis but not on results from RT-PCR
(Vennegoor et al, 1988; Kawakami et al, 1994). To investigate
further the presence ofgplOO transcripts in non-melanocytic cells,
we analysed different normal tissues. Figure 1 shows that 9 out of
11 of the tested samples were positive for gplOO, including seven
from fresh normal tissues and two from EBV-transformed B-cell
lines. The upper band that was sometimes observed in the fresh
normal tissues is derived from genomic DNA contamination. In
the gplOO sequence a small intron of 102 nt is present between the
primers that were used for the gplOO PCR. After DNAase
treatment of RNA before cDNA synthesis, the upper band is not
amplified. To confirm that the amplified product was derived from
gplOO transcripts, we cloned the PCR product and sequenced ten
independent clones. These all represented the gplOO cDNA
sequence (data not shown). In addition, anotherprimer set specific
for the 5' end of the gplOO mRNA yielded PCR products of the
expected size (not shown). In agreement with the literature, no
gplOO-specific hybridization could be detected by Northern blot-
ting (not shown) (Kawakami et al, 1994).
No gplOO protein was detected by Western blotting
Next, we analysed whether gplOO protein could be detected by
Western blotting (Figure 2). In Mel 603 and MZ-7.4-mel, positive
for gplOO by RT-PCR, gplOO protein was clearly detected by the
AZN-LAM antiserum. In the RCC cell lines Camejo, LE-9104-
RCC, SK-RC-7, LE-9211-RCC, which were all positive using RT-
PCR (not shown), no gplOO protein was detected. COS-7 cells
were negative forgplOO by RT-PCR and Western blotting.
Cytotoxicity
Although we did not detect gplOO protein by Western blotting in
the RCC cell lines that were all found to be positive by RT-PCR,
antigenic processing of a very small amount of gplOO protein
might still lead to MHC class I-mediated presentation of gplOO
peptides. As CTL recognition requires only a few antigenic
complexes on the cell surface, we tested a number of HLA-
A*0201-positive, gplOO-positive RCC cell lines for lysis using the
gplOO-specific TIL 1200 cytotoxic T-cell line (Bakker et al, 1995).
None ofthe HLA-A*0201-positive, gplOO-positive RCC cell lines
was lysed, whereas the control melanoma cell line Mel 624 was
readily lysed, suggesting that the level of expression of gplOO
occurs at an immunologically irrelevant level (Table 1).
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Low expression of gplOO transcripts in RCC
Although gplOO transcripts can be detected by RT-PCR in various
tissues, the gplOO protein is apparently notdetectedbycytotoxic T
cells. To investigate whether this is caused by low transcription
levels, we used semiquantitative PCR to compare the levels of
expression in the various cell lines with that of Mel 624.
Radioactive PCR for eitherP-actin or gplOO was perforihed using
21 and 25 cycles of amplification respectively, and the products
were run on acrylamide gels and quantified by phosphor-imaging.
The f-actin signals in Mel 624 and MCF-7 were similar, whereas
the signal in JY cells was higher at the different cDNA dilutions
(Figure 3). The gplOO signal, however, could readily be detected
in the melanoma cell line even after a 1:104-fold dilution, but 1:5
dilutions of the cDNA of MCF-7 and JY cells yielded barely
detectable gplOO-specific PCR products.
DISCUSSION
In this study we show that the melanocyte lineage-specific antigen
gplOO can be detected by RT-PCR in tumour cell lines originating
from tissues other than those of the melanocytic lineage. For the
gplOO PCR, we used 35 cycles of amplification, which is similar
to the number ofcycles that is used for the MART-l/MelanA and
RAGE-1 PCR - 35 and 33 respectively. GplOO PCR products
could even be detected with 30 cycles (not shown), indicating that
gplOO transcripts are relatively easily amplified from cell lines of
non-melanocytic origin. In contrast, transcription of MART-
l/MelanA or tyrosinase is strictly confined to melanocyte lineage-
specific cells. In normal tissues, including oesophagus, heart,
kidney, liver, lymph node, ovary, retina and thyroid, gplOO was
also detected by RT-PCR. Interestingly, we have not succeeded in
detecting gplOO in bloodfromhealthy donors. Using anested PCR
approach, however, Hersey et al. (personal communication) were
able to detect gplOO in the blood ofhealthy donors.
In contrast to other antigens that were identified by expression
cloning with specific T cells, the gplOO antigen was first identified
by antibody reactivity (Vennegoor et al, 1988; Adema et al, 1994).
Staining with MAbs NKI/beteb orHMB-45 couldonly be detected
in cells of the melanocytic lineage. After cloning of the gplOO
cDNA, the tissue-specific distribution was confirmed by Northern
analysis (Kawakami et al, 1994). The gplOO protein is a trans-
membrane protein that localizes primarily on the inside ofpreme-
lanosomal vesicles. The function of the protein is unknown at
present. Using RT-PCR, we show that there is a low level of tran-
scription of gplOO in virtually every cell type. Similar findings
were published by Chelly et al (1989), who showed that various
othertissue-specific genes couldbe detectedby RT-PCR in various
tissues. They suggested that modification of the chromatin struc-
ture during DNA replication allowed ubiquitous transcription
factors to bind to their cognate DNA elements, resulting in a low
level of transcription. The level of gplOO protein expressed,
however, is undetectable in these cell types. From these findings
we conclude that gplOO can still be considered as a marker for
cells ofmelanocytic lineage.
Screening ofcancer patients forthe presence oftumour antigens
as eligibility criteria for immunotherapeutical protocols is already
performed in the case of MAGE-3 (Marchand et al, 1995).
Moreover, tyrosinase-specific RT-PCR is used for the detection of
micrometastases in melanoma patients (Proebstle et al, 1996;
Rankin, 1996). To obtain clinically relevant information, screening
for gplOO expression within tumour material should be performed
by antibody staining. Ourexperiments suggest that lysis by gplOO-
specific T cells only correlates with expression of gplOO at the
protein level butnotwith RT-PCRexpression data. Alternatively, a
threshold value of gplOO expression, at which CTL recognition
still occurs, should be determined by semiquantitative PCR. A
similarsituation probably exists forthe melanoma-specific antigen
N-acetylglucosaminyl-transferase V, which could be detected by
RT-PCR but notby CTL, when the antigen was expressed at levels
lower than 8% of the reference (Guilloux et al, 1996). Our data
indicate that a tightly controlled, semiquantitative PCR protocol
should be developed in which gplOO is only detected when
expressed atbiologically revelant levels.
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